Back to today’s briefing

Story perspectives

Pfizer's Sasanlimab Shows Promise for Bladder Cancer Patients

4/29/2025

28 3

Summary

Story summary

Pfizer's phase 3 CREST trial for sasanlimab, an innovative anti-PD-1 monoclonal antibody, has achieved a significant milestone, demonstrating a 32% reduction in disease-related events for high-risk non-muscle invasive bladder cancer patients when combined with Bacillus Calmette-Guérin (BCG). The promising results are now in the hands of global health authorities for potential regulatory approval.

1 of 1

Story summary

Pfizer's phase 3 CREST trial for sasanlimab, an innovative anti-PD-1 monoclonal antibody, has achieved a significant milestone, demonstrating a 32% reduction in disease-related events for high-risk non-muscle invasive bladder cancer patients when combined with Bacillus Calmette-Guérin (BCG). The promising results are now in the hands of global health authorities for potential regulatory approval.